8-K: Vaxart Secures $700M Dynavax Deal, Extends Cash Runway

Vaxart announced a significant licensing agreement with Dynavax for its COVID-19 oral vaccine candidate, potentially worth up to $700 million plus royalties, alongside reporting its third-quarter 2025 financial results and extending its cash runway into Q2 2027.

Summary

• Entered into an exclusive, worldwide license and collaboration agreement with Dynavax Technologies Corporation for its COVID-19 oral vaccine candidate, with potential cumulative proceeds of up to $700 million plus tiered royalties.
• Received an upfront license fee of $25 million and a $5 million equity investment from Dynavax.
• Completed enrollment of approximately 5,400 participants in the COVID-19 Phase 2b trial, with topline data expected in late 2026 and data from the 400-person sentinel cohort anticipated in the first quarter of 2026.
• Reported additional supportive data from a Phase 1 clinical trial for its second-generation oral norovirus vaccine constructs, demonstrating stronger antibody responses.
• Cash, cash equivalents, and investments totaled $28.8 million as of September 30, 2025.
• The current cash runway is extended into the second quarter of 2027, following the upfront payment from Dynavax.
• Revenue for the third quarter of 2025 was $72.4 million, a significant increase from $4.9 million in the third quarter of 2024, primarily due to government contracts.
• Net loss for the third quarter of 2025 improved to $8.1 million, compared to a net loss of $14.1 million for the third quarter of 2024.

Sentiment

Score: 8

Explanation: The Dynavax licensing agreement is a major positive development, providing significant non-dilutive funding and validation for Vaxart's platform. The extension of the cash runway and improved financial results (reduced net loss, increased revenue) are also strong positives. While R&D expenses increased and a net loss persists, the strategic partnership and clinical progress outweigh these in terms of immediate sentiment.

Positives

• Secured an exclusive, worldwide license and collaboration agreement with Dynavax for the COVID-19 oral vaccine candidate, with potential cumulative proceeds of up to $700 million plus tiered royalties.
• Received an immediate $25 million upfront license fee and a $5 million equity investment from Dynavax.
• Successfully completed enrollment of approximately 5,400 participants in the COVID-19 Phase 2b trial.
• Reported positive Phase 1 data for second-generation oral norovirus vaccine constructs, showing robust increases in fecal IgA correlated with protection.
• Extended cash runway into the second quarter of 2027, providing longer financial stability.
• Reported significantly increased revenue of $72.4 million for Q3 2025, up from $4.9 million in Q3 2024, driven by government contracts.
• Reduced net loss to $8.1 million in Q3 2025 from $14.1 million in Q3 2024, and net loss per share to $0.04 from $0.06.

Negatives

• The company continues to operate at a net loss of $8.1 million for the third quarter of 2025.
• Research and development expenses significantly increased to $75.9 million in Q3 2025 from $15.1 million in Q3 2024, primarily due to the COVID-19 vaccine candidate trial.
• Stockholders' equity decreased significantly from $58.925 million at December 31, 2024, to $26.756 million at September 30, 2025.
• The next clinical trial for the norovirus candidate is pending a partnership or other funding, indicating potential reliance on external capital for this program.

Risks

• Uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates.
• Possibility of unfavorable new clinical data and further analyses of existing clinical data.
• Risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities.
• Uncertainty whether regulatory authorities will be satisfied with the design of and results from the clinical studies.
• The stop work order discussed in previous filings may result in further work on the COVID-19 Phase 2b trial being suspended or terminated.
• Decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities.
• Even if approved, Vaxart's product candidates may not achieve broad market acceptance.
• A Vaxart collaborator (Dynavax) may not attain development and commercial milestones.
• Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart's or its partners' control, including difficulties in production, scaling up, costs, yields, quality control, personnel shortages, raw material shortages, and compliance with regulations.
• Inability to obtain, maintain, and enforce necessary patent and other intellectual property protection.
• Inadequate capital resources and the ability to obtain sufficient capital to fund operations on acceptable terms, if at all.
• Ability to resolve pending legal matters.
• Impact of government healthcare proposals and policies.
• Competitive factors in the vaccine market.

Future Outlook

Vaxart anticipates reporting multiple datasets in 2026 from its COVID-19 Phase 2b trial, including topline data from the sentinel cohort in Q1 2026 and full topline data in late 2026. The company expects to initiate the next clinical trial for its norovirus vaccine candidate in 2026, contingent on securing a partnership or other funding. Management is actively exploring various strategies, including business development partnerships and non-dilutive funding, to further extend its cash runway beyond Q2 2027 and achieve upcoming clinical and regulatory milestones.

Management Comments

• "Our commitment at Vaxart is to advance the science of our novel, oral vaccine platform."
• "The collaboration agreement with Dynavax is an important step forward in realizing this goal as it both brings in a proven partner to the future development and commercialization of our oral COVID-19 vaccine candidate and enhances our financial position."
• "Following the completed enrollment of approximately 5,400 participants in our COVID-19 Phase 2b trial, we are on track to report multiple datasets in 2026 that we believe will provide useful insights and a strong foundation of evidence that could further validate our platform."
• "Additionally, we showcased positive topline results from our Phase 1 trial demonstrating that our second-generation oral pill norovirus vaccine constructs produced much stronger antibody responses than our first-generation constructs at various medical meetings globally."
• "We continue to explore value-creating partnership opportunities for our norovirus candidate as well as our HPV and flu programs, which have demonstrated promising data in preclinical and clinical studies."

Industry Context

The agreement with Dynavax positions Vaxart's oral COVID-19 vaccine candidate with a partner experienced in vaccine development and commercialization, potentially accelerating its path to market in a competitive landscape dominated by injectable vaccines. The focus on an oral pill vaccine platform addresses a significant market need for easier administration, storage, and distribution, particularly in global health initiatives. The continued development of norovirus, HPV, and flu programs aligns with broader industry trends towards diversified vaccine portfolios and innovative delivery methods, although securing partnerships remains crucial for advancing these candidates.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies' projects or results.
• Vaxart's oral vaccine platform aims to differentiate itself from traditional injectable vaccines by offering advantages in administration (pill form), storage (no refrigeration), and distribution, which could be a significant competitive advantage if efficacy and safety are proven comparable or superior.
• The potential cumulative proceeds of up to $700 million plus royalties from the Dynavax agreement for a single vaccine candidate is a substantial deal in the biotech licensing space, indicating strong partner confidence in the platform's potential.
• The completion of a Phase 2b trial with 5,400 participants for a COVID-19 vaccine is a significant milestone, comparable in scale to late-stage trials conducted by major pharmaceutical companies for novel vaccine candidates.

Legal Proceedings

• The company's ability to resolve pending legal matters is identified as a risk factor.

Stakeholder Impact

• Shareholders: Potential for significant value creation from the Dynavax deal, extended cash runway, and positive clinical progress. However, continued net losses and potential future dilution if non-dilutive funding is not secured for all programs remain considerations.
• Employees: Continued employment and potential growth opportunities as clinical programs advance and partnerships are formed.
• Customers (future vaccine recipients): Potential for an oral, easily administrable vaccine for COVID-19 and other diseases, offering convenience and improved access.
• Partners (Dynavax): Dynavax gains exclusive worldwide rights to a promising oral COVID-19 vaccine candidate, expanding its vaccine portfolio.
• Creditors: Extended cash runway reduces immediate liquidity concerns.

Next Steps

• Vaxart will retain full operational and financial responsibility for the oral COVID-19 vaccine program through the completion of the ongoing Phase 2b clinical trial and the subsequent End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA).
• Dynavax will pay an additional fee of $50 million to Vaxart after receiving the results of the Phase 2b clinical trial, unless Dynavax elects not to assume responsibility for continued clinical development.
• Topline data from the 400-person sentinel cohort of the COVID-19 Phase 2b trial is anticipated in the first quarter of 2026.
• Topline data from the full COVID-19 Phase 2b trial is anticipated in late 2026.
• Vaxart intends to publish the complete results of its Phase 1 norovirus study in a peer-reviewed journal.
• Pending a partnership or other funding, Vaxart expects to initiate the next clinical trial for its norovirus vaccine in 2026.
• Vaxart senior management will host a conference call on November 13, 2025, at 4:30 p.m. ET.
• Vaxart senior management will host a live stockholder fireside chat on November 18, 2025, at 4:30 p.m. ET.
• The company will continue to explore value-creating partnership opportunities for its norovirus candidate, HPV, and flu programs.
• The company will continue to explore various strategies to extend its cash runway through business development partnerships and non-dilutive funding options.

Key Dates

Recommendation

The Dynavax licensing agreement represents a significant validation of Vaxart's oral vaccine platform and provides substantial non-dilutive capital, including an immediate $30 million and potential future payments up to $700 million plus royalties. This deal, combined with the extension of the cash runway into Q2 2027, significantly de-risks the company's financial position and provides a clear path for the continued development of its lead COVID-19 candidate. The improved net loss and substantial revenue increase from government contracts further strengthen the financial picture. While R&D expenses are high due to ongoing trials, this is expected for a clinical-stage biotech. The positive Phase 1 norovirus data and ongoing exploration of partnerships for other programs indicate a robust pipeline. The potential for an oral vaccine to address global health needs, coupled with a strong strategic partnership, makes Vaxart an attractive investment for long-term growth, despite the inherent risks of clinical development.

Keywords

Vaxart, VXRT, Dynavax, COVID-19 vaccine, oral vaccine, pill vaccine, norovirus vaccine, Phase 2b trial, clinical-stage biotechnology, SEC filing, financial results, biotech, vaccine development, licensing agreement, BARDA contract, immunogenicity, efficacy, IgA, HPV vaccine, influenza vaccine, drug development, biopharmaceutical